Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Essential Role of IL-17 as the Pathogenetic Link between Psoriasis and Metabolic-Associated Fatty Liver Disease.
Olveira A, Augustin S, Benlloch S, Ampuero J, Suárez-Pérez JA, Armesto S, Vilarrasa E, Belinchón-Romero I, Herranz P, Crespo J, Guimerá F, Gómez-Labrador L, Martín V, Carrascosa JM. Olveira A, et al. Among authors: armesto s. Life (Basel). 2023 Feb 2;13(2):419. doi: 10.3390/life13020419. Life (Basel). 2023. PMID: 36836776 Free PMC article. Review.
Redefining the therapeutic objective in psoriatic patients candidates for biological therapy.
Carretero G, Puig L, Carrascosa JM, Ferrándiz L, Ruiz-Villaverde R, de la Cueva P, Belinchon I, Vilarrasa E, Del Rio R, Sánchez-Carazo JL, López-Ferrer A, Peral F, Armesto S, Eiris N, Mitxelena J, Vilar-Alejo J, A Martin M, Soria C; from the Spanish Group of Psoriasis. Carretero G, et al. Among authors: armesto s. J Dermatolog Treat. 2018 Jun;29(4):334-346. doi: 10.1080/09546634.2017.1395794. Epub 2017 Nov 21. J Dermatolog Treat. 2018. PMID: 29099667 Review.
Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group.
Del Alcázar E, Suárez-Pérez JA, Armesto S, Rivera R, Herrera-Acosta E, Herranz P, Martín I, Montesinos E, Hospital M, Vilarrasa E, Ferran M, Ruiz-Villaverde R, Sahuquillo-Torralba A, Ruiz-Genao DP, Pérez-Barrio S, Muñoz C, Llamas M, Valentí F, Mitxelena MJ, López-Ferrer A, Carretero G, Vidal D, Mollet J, Belinchón I, Carrascosa JM. Del Alcázar E, et al. Among authors: armesto s. J Eur Acad Dermatol Venereol. 2020 Dec;34(12):2821-2829. doi: 10.1111/jdv.16439. Epub 2020 Jun 17. J Eur Acad Dermatol Venereol. 2020. PMID: 32271966
Secukinumab is effective in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting.
Reolid A, Armesto S, Sahuquillo-Torralba A, Torres T, Feltes R, Vilarrasa E, Belinchón I, Cueva P, Rodríguez L, Romero-Maté A, Vidal D, Coto-Segura P, Herrera-Acosta E, Riera-Monroig J, Salgado L, Llamas-Velasco M, Daudén E. Reolid A, et al. Among authors: armesto s. J Am Acad Dermatol. 2022 Sep;87(3):705-709. doi: 10.1016/j.jaad.2022.05.047. Epub 2022 May 28. J Am Acad Dermatol. 2022. PMID: 35640798 Free article. No abstract available.
Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting.
Chicharro P, Llamas-Velasco M, Armesto S, Herrera-Acosta E, Vidal D, Vilarrasa E, Rivera R, De la Cueva P, Martorell-Calatayud A, Ballescà F, Belinchón I, Carretero G, Rodríguez L, Romero-Maté A, Pujol-Montcusí J, Salgado L, Sahuquillo-Torralba A, Coto-Segura P, Baniandrés-Rodríguez O, Feltes R, Alsina M, Daudén E. Chicharro P, et al. Among authors: armesto s. Dermatol Ther. 2022 Aug;35(8):e15653. doi: 10.1111/dth.15653. Epub 2022 Jun 29. Dermatol Ther. 2022. PMID: 35731640
High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting.
Martos-Cabrera L, Llamas-Velasco M, Armesto S, Herrera-Acosta E, Vidal D, Vilarrasa E, Rivera-Diaz R, de la Cueva P, Martorell-Calatayud A, Ballescá F, Belinchón I, Carretero G, Rodríguez L, Romero-Maté A, Pujol-Montcusí J, Salgado-Boquete L, Sahuquillo-Torralba A, Coto-Segura P, Baniandrés O, Feltes R, Alsina M, Daudén E. Martos-Cabrera L, et al. Among authors: armesto s. Int J Dermatol. 2023 Mar;62(3):e146-e149. doi: 10.1111/ijd.16365. Epub 2022 Jul 22. Int J Dermatol. 2023. PMID: 35867958 No abstract available.
Drug survival of adalimumab biosimilars in real-world treatment of psoriasis: A Spanish multicenter study.
López-Ferrer A, Vilarrasa E, Armesto S, Santos-Juanes J, Galache C, Carretero G, Sahuquillo A, Salgado-Boquete L, Del Alcázar E, González-Cantero A, Martorell A, Rivera-Díaz R, Mitxelena-Ezeiza J, Mateu A, Belinchón I, Llamas-Velasco M, Riera-Monroig J, Lázaro A, López-Estebaranz JL, Gich I, Puig L. López-Ferrer A, et al. Among authors: armesto s. Dermatol Ther. 2022 Nov;35(11):e15831. doi: 10.1111/dth.15831. Epub 2022 Sep 27. Dermatol Ther. 2022. PMID: 36109488 No abstract available.
Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis Group.
Rocamora V, Crespi L, Ferran M, Llamas-Velasco M, Del Alcázar E, Carrascosa JM, Beltran E, Urruticoechea-Arana A, Estebaranz JLL, Vidal D, Riera J, Rodríguez L, Armesto S, Fernández JM, Aparicio G, Pérez S, Porcar S, Montesinos E, Gallardo F. Rocamora V, et al. Among authors: armesto s. Dermatol Ther. 2022 Nov;35(11):e15865. doi: 10.1111/dth.15865. Epub 2022 Oct 9. Dermatol Ther. 2022. PMID: 36175141
Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients.
Chicharro P, Llamas-Velasco M, Armesto S, Herrera Acosta E, Vidal D, Vilarrasa E, Rivera-Diaz R, De-la-Cueva P, Martorell-Calatayud A, Ballescà F, Belinchon I, Carretero G, Rodriguez L, Romero-Maté A, Pujol-Montcusí J, Salgado L, Sahuquillo-Torralba A, Coto-Segura P, Baniandrés Rodríguez O, Feltes R, Riera-Monroig J, Dauden E. Chicharro P, et al. Among authors: armesto s. Dermatol Ther. 2022 Dec;35(12):e15929. doi: 10.1111/dth.15929. Epub 2022 Oct 19. Dermatol Ther. 2022. PMID: 36223184
52 results